15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis
Key Takeaways
Acute uncomplicated cystitis is predominantly caused by uropathogenic Escherichia coli (75%–90%) and Staphylococcus saprophyticus (5%–15%), with diagnosis confirmed by acute dysuria, frequency, urgency, and urinalysis demonstrating leukocyte esterase, nitrites, and pyuria (>5–10 WBC/hpf).
First-line empiric antimicrobials per IDSA guidelines include nitrofurantoin monohydrate/macrocrystals (100 mg BID x 5 days; avoid if eGFR <30 mL/min or at 36–42 weeks gestation), trimethoprim-sulfamethoxazole DS (160/800 mg BID x 3 days; avoid if local resistance >20% or in first trimester and near term), and fosfomycin trometamol (3 g single oral sachet); fluoroquinolones are strictly reserved for complicated infections.
Recurrent UTIs (≥2 culture-confirmed episodes in 6 months or ≥3 in 12 months) warrant non-antimicrobial behavioral modifications, topical vaginal estrogen in postmenopausal women with genitourinary syndrome of menopause (GSM), and postcoital or low-dose daily antimicrobial prophylaxis.
Asymptomatic bacteriuria (ASB, ≥100,000 CFU/mL) requires universal urine culture screening at the initial prenatal visit (12–16 weeks) and mandatory treatment (nitrofurantoin, amoxicillin-clavulanate, or cephalexin) with a test-of-cure culture 1–2 weeks post-treatment to prevent progression to acute pyelonephritis (which occurs in 20%–40% of untreated gravidas).
Acute pyelonephritis presents with fever, rigors, flank pain, and costovertebral angle (CVA) tenderness; pregnant women, patients with intractable vomiting, and those with sepsis signs require mandatory hospital admission for IV broad-spectrum beta-lactams (e.g., ceftriaxone), while microscopic hematuria (≥3 RBCs/hpf) requires excluding transient causes prior to AUA risk-stratified urologic referral.
Epidemiology & Microbiology of UTIs in Women
Urinary tract infections (UTIs) affect over 50% to 60% of women during their lifetime. Distinct biological and behavioral mechanisms drive this female predisposition:
- Anatomical Vulnerability: The female urethra is short (~4 cm compared to ~20 cm in biological males) and terminates in close proximity to the vulvar introitus and perianal region, facilitating the retrograde ascent of enteric bacteria into the bladder.
- Sexual Intercourse: Coitus mechanically massages periurethral and introital flora into the bladder lumen. Spermicide use (nonoxynol-9) and diaphragms disrupt the protective lactobacilli of the vaginal microbiota.
- Estrogen Deficiency & Menopause: In reproductive-age women, circulating 17-beta-estradiol supports a glycogen-rich vaginal epithelium colonized by Lactobacillus species, maintaining an acidic pH (3.8–4.5) that inhibits Enterobacteriaceae. In postmenopausal women with genitourinary syndrome of menopause (GSM), loss of estrogen causes epithelial atrophy, depletion of lactobacilli, and an elevated vaginal pH (>5.0), facilitating uropathogen colonization.
Microbiology of Uncomplicated UTIs
- Uropathogenic Escherichia coli (UPEC): Causes 75% to 90% of uncomplicated cystitis and pyelonephritis cases. UPEC strains express type 1 fimbriae (adhering to bladder uroplakins) and P-fimbriae (binding to renal digalactoside receptors).
- Staphylococcus saprophyticus: Coagulase-negative Gram-positive staphylococcus causing 5% to 15% of acute cystitis in young, sexually active women.
- Other Enterobacteriaceae: Klebsiella pneumoniae, Proteus mirabilis (urease-producing rod that hydrolyzes urea into ammonia, elevating urine pH >7.5 and promoting struvite calculi), and Enterobacter species.
- Gram-Positive Organisms: Enterococcus faecalis occurs primarily in older women, catheterized patients, or those with structural urologic anomalies.
Acute Uncomplicated Cystitis: Presentation & Diagnostic Urinalysis
Acute uncomplicated cystitis is a symptomatic infection confined to the bladder in healthy, non-pregnant, premenopausal females with anatomically normal urinary tracts.
Clinical Presentation
Patients present with acute-onset irritative lower urinary tract symptoms:
- Dysuria: Internal urethral or suprapubic burning during micturition.
- Frequency & Urgency: Sensation of needing to void small volumes at frequent intervals.
- Suprapubic Discomfort: Dull aching or pressure over the lower hypogastrium.
- Absence of Vaginal Symptoms: Absence of vaginal discharge, pruritus, or deep dyspareunia yields a high post-test probability (>90%) for true cystitis. If vaginal symptoms coexist, evaluate for vaginitis, cervicitis, or pelvic inflammatory disease (PID).
Urinalysis Interpretation
Evaluate a clean-catch midstream urine specimen to minimize perineal contamination (<5 squamous epithelial cells/hpf indicates an adequate sample):
- Leukocyte Esterase (LE): Enzyme released by activated neutrophils indicating pyuria (sensitivity 75%–90%, specificity ~95%).
- Nitrites: Gram-negative enteric rods reduce dietary nitrates to nitrites. Highly specific (>95%), but sensitivity is 50%–60% because bacterial incubation requires ~4 hours in the bladder. False negatives occur with Gram-positive pathogens (S. saprophyticus, Enterococcus) or frequent voiding.
- Microscopic Pyuria: >5 to 10 WBC/hpf on centrifuged urine; present in nearly all genuine UTIs.
- Microscopic Hematuria: Present in ~30% of acute uncomplicated cystitis episodes due to mucosal capillary friability; resolves within 4 to 6 weeks following infection clearance.
Note
In healthy, non-pregnant premenopausal women presenting with classic acute dysuria and frequency without vaginal discharge, empiric therapy can be initiated without a pre-treatment urine culture. Urine culture and susceptibility testing are mandatory for suspected pyelonephritis, recurrent UTIs, pregnancy, treatment failure, or complicated hosts.
First-Line Antimicrobial Regimens & Antimicrobial Stewardship
The Infectious Diseases Society of America (IDSA) establishes evidence-based first-line regimens for acute uncomplicated cystitis to balance clinical cure against ecological collateral damage (multidrug resistance and C. difficile colitis).
| Antimicrobial Agent | Standard Dosing & Duration | Mechanism & Spectrum | Gestational & Renal Caveats | Common Adverse Effects |
|---|---|---|---|---|
| Nitrofurantoin Monohydrate / Macrocrystals (Macrobid) | 100 mg PO BID x 5 days | Reduced by bacterial flavoproteins into active intermediates attacking ribosomal proteins, DNA, and RNA. High urinary concentration with minimal systemic tissue levels. | Avoid if eGFR <30 mL/min/1.73 m² (inadequate urine concentration). Avoid near term (36–42 weeks) due to risk of neonatal hemolytic anemia. | Nausea, headache, anorexia, dark urine; rare pulmonary toxicity or peripheral neuropathy with prolonged use. |
| Trimethoprim-Sulfamethoxazole DS (TMP-SMX 160/800 mg) | 1 DS tablet PO BID x 3 days | Sequential blockade of bacterial folic acid synthesis. High urinary and tissue concentrations. | First-line ONLY if local E. coli resistance is <20%. Contraindicated in 1st trimester (folate antagonism) and near term (kernicterus). | Rash, photosensitivity, hyperkalemia, gastrointestinal upset, blood dyscrasias. |
| Fosfomycin Trometamol | 3 g PO single-dose sachet dissolved in cold water | Inactivates enolpyruvyl transferase (MurA), blocking peptidoglycan cell wall synthesis. | Safe across all trimesters of pregnancy. No dosage adjustment required in mild-to-moderate renal insufficiency. | Diarrhea, headache, nausea; slightly lower clinical cure rate than 5-day nitrofurantoin. |
Important
Fluoroquinolones (Ciprofloxacin, Levofloxacin): Fluoroquinolones are strictly reserved for complicated infections, pyelonephritis, or when first-line agents cannot be used. The FDA and IDSA issue explicit warnings restricting fluoroquinolones due to severe boxed warnings: tendonitis and tendon rupture (Achilles tendon), QT prolongation, peripheral neuropathy, central nervous system toxicities, glycemic dysregulation, and aortic aneurysm rupture, alongside high rates of collateral resistance.
Recurrent Urinary Tract Infections (rUTI)
Recurrent UTI is defined as ≥2 culture-confirmed symptomatic episodes within 6 months, or ≥3 culture-confirmed episodes within 12 months.
Non-Antimicrobial & Prophylactic Strategies
- Hydration: Consuming an additional 1.5 L of water daily reduces UTI recurrence by nearly 50% via continuous mechanical flushing of the bladder.
- Postcoital Voiding: Promotes rapid hydrodynamic clearance of bacteria inoculated during intercourse.
- Cranberry Proanthocyanidins (PACs): Standardized cranberry extract (36 mg soluble PACs daily) inhibits P-fimbriated E. coli adherence to uroepithelial receptors.
- Topical Vaginal Estrogen: In postmenopausal women with GSM, low-dose topical vaginal estrogen (estradiol cream 0.5 g, estradiol 10 mcg tablet, or estradiol vaginal ring) is the most effective non-antimicrobial strategy. It reverses mucosal atrophy, restores lactobacilli, lowers vaginal pH to <4.5, and reduces recurrence by over 60%. (Oral hormone therapy does not replicate this benefit).
- Antimicrobial Prophylaxis: When non-pharmacologic measures fail, postcoital single-dose prophylaxis (nitrofurantoin 50–100 mg, TMP-SMX SS 80/400 mg, or cephalexin 250 mg within 2 hours of intercourse) or continuous daily low-dose prophylaxis (nitrofurantoin 50 mg at bedtime for 6–12 months) may be prescribed after confirming eradication of prior infection.
Asymptomatic Bacteriuria (ASB) in Pregnancy: Universal Screening & Treatment
Asymptomatic bacteriuria is defined as the isolation of ≥100,000 CFU/mL of a single uropathogen from a clean-catch midstream urine specimen in an individual without urinary symptoms.
Universal Screening Mandate
In non-pregnant women, ASB is benign and must never be screened or treated. In pregnancy, universal screening is mandatory:
- Timing: Screen all gravidas with a clean-catch urine culture at the initial prenatal visit (12 to 16 weeks gestation). Urine dipstick and microscopy have low sensitivity and cannot substitute for quantitative culture.
- Gestational Risks: Progesterone-induced ureteral smooth muscle relaxation produces peristaltic hypomotility, hydroureter, and urinary stasis, while the enlarging dextrorotated gravid uterus mechanically compresses the ureters. Consequently, 20% to 40% of untreated gravidas with ASB progress to acute pyelonephritis, leading to septic shock, acute respiratory distress syndrome (ARDS), preterm labor, and low birth weight.
- Gestational Regimens: Treat with a 5- to 7-day course of pregnancy-compatible antimicrobials: cephalexin 500 mg PO TID/QID x 5–7 days, amoxicillin-clavulanate 500/125 mg PO BID x 5–7 days, or nitrofurantoin 100 mg PO BID x 5–7 days (safe in second trimester; avoid at 36–42 weeks).
- Mandatory Test-of-Cure: Obtain a follow-up urine culture 1 to 2 weeks post-treatment completion, followed by monthly screening cultures throughout pregnancy.
Acute Pyelonephritis: Triage, Inpatient Criteria & Treatment
Acute pyelonephritis is an invasive infection of the renal parenchyma and renal pelvis, ascending from the lower urinary tract.
Clinical Presentation & Diagnostics
- Clinical Triad: Systemic fever (>38.0°C / 100.4°F), rigors/chills, and unilateral or bilateral flank pain / costovertebral angle (CVA) tenderness, accompanied by nausea, vomiting, and anorexia.
- Urinalysis: Pyuria, bacteriuria, and white blood cell (WBC) casts (pathognomonic for renal parenchymal inflammation, differentiating pyelonephritis from lower tract cystitis).
Triage & Admission Criteria
- Outpatient Oral Management: Reserved strictly for mild, uncomplicated cases in reliable, non-pregnant, immunocompetent, hemodynamically stable patients tolerating oral fluids with reliable follow-up. Regimen: oral ciprofloxacin 500 mg PO BID x 7 days or levofloxacin 750 mg PO daily x 5 days, preceded by an initial dose of IV ceftriaxone 1 g in clinic if local fluoroquinolone resistance exceeds 10%.
- Mandatory Inpatient Admission Criteria:
- ALL pregnant women (due to high risks of sepsis, ARDS, and preterm labor).
- Inability to tolerate oral hydration or medications (intractable vomiting).
- Hemodynamic instability, persistent tachycardia, hypotension, or septic signs.
- High persistent fever (>38.5°C), severe unremitting pain, or toxic appearance.
- Suspected urinary tract obstruction or nephrolithiasis.
- Significant renal impairment or severe immunocompromise.
- Inpatient Regimen: IV ceftriaxone 1 g every 24 hours, ampicillin plus gentamicin, or cefepime. Continue parenteral therapy until afebrile for 24 to 48 hours, then transition to an oral agent based on susceptibilities to complete a 10- to 14-day total antimicrobial course.
Microscopic Hematuria Workup in Women
Microscopic hematuria is defined by the American Urological Association (AUA) as ≥3 red blood cells per high-power field (RBCs/hpf) on microscopic examination of a centrifuged clean-catch urine specimen. Positive chemical dipsticks require microscopic confirmation.
Stepwise Clinical Evaluation
- Exclude Benign / Transient Causes: Active menses (repeat UA after menses clears or obtain a catheterized specimen), vigorous exercise within 48 hours, sexual intercourse, trauma, or acute UTI.
- Evaluate & Treat UTI: If pyuria and bacteriuria accompany hematuria, treat the infection and repeat urinalysis with microscopy 6 weeks post-treatment to confirm complete clearance.
- AUA Risk Stratification & Referral: If microscopic hematuria (≥3 RBCs/hpf) persists without identifiable transient causes, stratify into low, intermediate, or high risk based on age (>50 years), smoking history (pack-years), and degree of hematuria (>25 RBCs/hpf). Intermediate- and high-risk patients warrant urology referral for cystoscopy and multiphasic CT urography to evaluate for urothelial and renal malignancy.
Nephrolithiasis (Renal Stones)
Kidney stones affect roughly 1 in 11 U.S. adults. About 70%–80% are calcium oxalate; struvite (magnesium ammonium phosphate) stones form in alkaline urine infected with urease-producing organisms such as Proteus and are relatively more common in women because of their higher UTI rate.
- Presentation: Sudden colicky flank pain radiating to the groin or labia, nausea, and hematuria (present in most cases). Fever with an obstructing stone is a urologic emergency: an infected, obstructed kidney needs urgent decompression (stent or nephrostomy) plus antibiotics.
- Imaging: Low-dose noncontrast CT is the reference test outside pregnancy. In pregnancy, start with renal ultrasound; MRI or low-dose CT is a second step if needed.
- Acute management: NSAIDs are first-line analgesics (avoid NSAIDs in pregnancy after about 20 weeks), plus antiemetics and hydration. Most stones ≤5 mm pass spontaneously; the AUA supports an alpha-blocker such as tamsulosin as medical expulsive therapy for distal ureteral stones ≤10 mm. Refer for stones >10 mm, infection, acute kidney injury, a solitary kidney, or uncontrolled pain.
- Prevention: Drink enough to produce more than 2.5 L of urine daily, keep normal dietary calcium (1,000–1,200 mg/day; low-calcium diets raise oxalate absorption), limit sodium and animal protein, and send a recovered stone for analysis. A 24-hour urine study guides thiazides (hypercalciuria) or potassium citrate (hypocitraturia).
A 28-year-old female at 37 weeks gestation presents to the clinic with a 2-day history of burning with urination, frequency, and suprapubic cramping. She denies fever, chills, back pain, nausea, or vaginal discharge. On physical examination, her vital signs are normal, and there is mild suprapubic tenderness without costovertebral angle tenderness. A clean-catch urinalysis demonstrates 2+ leukocyte esterase, positive nitrites, and 25 WBC/hpf. Which antimicrobial regimen is the most appropriate first-line therapy for this patient at this gestational age?
Nitrofurantoin monohydrate/macrocrystals 100 mg orally twice daily for 5 days.
Cephalexin 500 mg orally four times daily for 5 to 7 days.
Trimethoprim-sulfamethoxazole double strength (160/800 mg) orally twice daily for 3 days.
Ciprofloxacin 500 mg orally twice daily for 3 days.
A 62-year-old postmenopausal female presents to the women's health clinic complaining of acute dysuria and urinary frequency. Over the past 9 months, she has experienced four culture-confirmed episodes of acute cystitis, all caused by Escherichia coli and successfully treated with short courses of antibiotics. On physical examination, her vulvovaginal mucosa is pale, thinned, and dry with diminished rugal folds and a vaginal pH of 5.8. Urinalysis confirms acute cystitis. In addition to prescribing targeted antimicrobial therapy for the acute infection, which non-antimicrobial preventive intervention provides the greatest evidence-based reduction in recurrent UTIs for this patient?
Initiate daily oral conjugated equine estrogens combined with medroxyprogesterone acetate.
Advise the daily consumption of 16 ounces of commercial cranberry juice cocktail.
Prescribe low-dose topical vaginal estrogen cream or an estradiol vaginal ring.
Initiate continuous urinary acidification using high-dose oral methenamine hippurate without topical therapy.
A 24-year-old female at 20 weeks gestation presents to the clinic complaining of right-sided flank pain, shaking chills, nausea, and two episodes of vomiting over the preceding 12 hours. Her temperature is 38.6°C (101.5°F), pulse is 112 bpm, and blood pressure is 106/62 mmHg. Physical examination reveals marked right costovertebral angle (CVA) tenderness and mild uterine irritability without cervical dilation. Urinalysis demonstrates 3+ leukocyte esterase, positive nitrites, numerous WBCs, and white blood cell casts. What is the most appropriate clinical management plan for this patient?
Admit the patient to the hospital for intravenous hydration and parenteral broad-spectrum beta-lactam therapy (such as IV ceftriaxone).
Prescribe oral ciprofloxacin 500 mg twice daily for 7 days and discharge home with close outpatient follow-up.
Administer an intramuscular dose of ceftriaxone 1 g in the clinic and discharge on oral nitrofurantoin 100 mg twice daily for 10 days.
Prescribe oral amoxicillin-clavulanate 500/125 mg twice daily, oral ondansetron for nausea, and reassess in clinic in 48 hours.
Sections you finish are checked off in the contents.